On April 17, 2026 Biolojic Design, a biotechnology company that uses AI to transform antibodies into multifunctional, programmable medicines, reported new preclinical data demonstrating the strong anti-tumor properties of its multibody-drug conjugate BD200. The data are being presented at the 2026 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, being held April 17-22, 2026 in San Diego.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We’re excited to share data from the first ever multibody-drug conjugate, which has the potential to transform ADC technology and, as our data suggest, lead to more efficacious and safer treatment," said Yanay Ofran, PhD, CEO and founder of Biolojic Design. "The unique ability of a multibody to adapt to the heterogeneity of tumor antigen expression makes it an ideal base for an ADC, potentially enhancing anti-tumor activity while reducing the amount of drug needed to dose. Combined with the linker/payload we designed, BD200 has a dramatically improved therapeutic index compared to other ADCs. We look forward to initiating our first clinical trial of BD200 later this year."
BD200 is a multibody-drug conjugate, an ADC that is based on a multibody, a new kind of AI-designed antibody that can conditionally bind to multiple targets while maintaining the natural format of a human IgG antibody. Unlike conventional bi-specific antibodies, which have fixed binding profiles, each arm of BD200 can bind to either Trop-2 or Nectin-4. While both may be expressed by a cancer cell, the unique ability of each arm of BD200 to bind to either target helps it overcome target expression heterogeneity while maintaining full avidity on cells. This enables BD200 to deliver more of its cytotoxic payload to the tumor and reduce off tumor and systemic toxicity.
The data being presented at AACR (Free AACR Whitepaper) show:
BD200 demonstrated strong anti-tumor responses across patient derived xenografts of triple negative breast cancer, bladder, cervical and esophageal cancer, as well as gastric cancer in cell line-derived xenograft models
BD200 showed strong activity in tumor models derived from patients that were resistant to other ADCs
In mice bearing human tumors that developed resistance to other ADCs, BD200 led to deep regressions, even in larger tumors (tumor volume >2000mm3)
BD200 demonstrated superior uptake in a Trop-2/Nectin-4 dual-expressing breast cancer cell line when compared to currently marketed antibodies and antibody-drug conjugates that bind to either Trop-2 or Nectin-4 alone
In cell lines resistant to ADCs that bind only to Nectin-4, switching to BD200 restored potent anti-tumor activity
About BD200
BD200 is a potent, first-in-class multibody-drug conjugate that targets two proteins,Trop-2 and Nectin-4, that are co-expressed in various solid tumors, including bladder, breast, lung and head and neck cancers. These proteins drive tumor progression, adhesion, and metastasis. Their expression can be heterogeneous, meaning that patients’ tumors may express these proteins at varying levels. By flexibly targeting both Trop-2 and Nectin-4, BD200 has the potential for enhanced activity, despite the heterogenous expression of the individual targets. BD200 has shown significant anti-tumor activity across multiple human tumor models.
(Press release, Biolojic Design, APR 17, 2026, View Source [SID1234664513])